Loading
A phase 1/2 trial of bevacizumab (glioblastoma use) and fOLFIRI (5-FU, leucovorin, irinotecan) in colorectal cancer, run by Luye Pharma Group Ltd., not yet recruiting.
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation is a phase 1/2, interventional study registered as NCT07391566 by Luye Pharma Group Ltd., with a registry enrolment figure of 99 participants, started 2026-03-31 and due to reach its primary completion in 2028-12-31. Interventions recorded: LPM6690176; Bevacizumab; FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan). Conditions listed: Metastatic Colorectal Cancer (mCRC). Primary outcome: Phase Ib: Dose-limiting toxicities (DLTs); Phase Ib: Maximum tolerated dose (MTD); Phase 1b: Recommended Phase 2 Dose (RP2D). Colorectal eligibility wording from the registry: "Histologically confirmed metastatic colorectal cancer (CRC) with RAS mutation;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.